VanEck Pharmaceutical ETF (NQ:PPH)

114.79 -0.14 (-0.12%)

Official Closing Price Updated: 4:15 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about VanEck Pharmaceutical ETF

< Previous 1 2 3 Next >

A Look At Pharma ETFs Post Q1 Earnings ↗

May 07, 2024

Pharma ETFs have delivered mixed performances over the past month.

Via Talk Markets

Topics ETFs

ETFs To Buy As Eli Lilly Beats Q1 Earnings, Lifts Outlook ↗

May 01, 2024

Eli Lilly and Company posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. Investors seeking to tap the opportune moment could bet on ETFs having the largest...

Via Talk Markets

Topics ETFs

3 Weight-Loss ETFs to Profit From the Obesity Drug Boom ↗

April 17, 2024

Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment.

Via InvestorPlace

Topics ETFs

Novo Nordisk's Game-Changer: FDA Approves Weight Loss Sensation Wegovy For Heart Health, Potential Insurance Coverage ↗

March 08, 2024

Novo Nordisk's Wegovy receives FDA approval for expanded use, targeting a significant reduction in cardiovascular events and weight management.

Via Benzinga

The Top 3 ETFs to Buy in March 2024 ↗

March 07, 2024

Simplify your investment strategy through these top ETFs to buy, offering an excellent blend of diversification and upside.

Via InvestorPlace

Topics ETFs

11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields ↗

February 28, 2024

A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year.

Via Benzinga

A Look At Pharma ETFs After Q4 Earnings ↗

February 12, 2024

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth.

Via Talk Markets

Topics ETFs

5 ETF Zones Scaling New Highs At The Start Of 2024 ↗

January 08, 2024

The start of 2024 has been weak for the global stock market after a blockbuster 2023. Still, a few corners of the stock market are outperforming, pushing ETFs to new 52-week highs.

Via Talk Markets

Topics ETFs

Government-granted Patent Monopolies Are Not The Free Market ↗

December 29, 2023

Our system for developing new drugs is a disaster. While we can point to great successes, they come at enormous cost. We will spend over $600B this year on prescription and non-prescription drugs -...

Via Talk Markets

Topics Intellectual Property

Preparing For The Next Short-Term Rally Higher ↗

August 12, 2023

The short-term downtrend appears set to continue. The market is taking the time it needs to consolidate near its short-term trend lows in order to prepare a base from which it can begin its next...

Via Talk Markets

Pharma ETFs in Focus Post Q2 Earnings ↗

August 11, 2023

Second-quarter earnings for the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 30.7% on 5% revenue growth.

Via Talk Markets

Topics ETFs

The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023 ↗

July 21, 2023

Trading below a 15 forward price-to-earnings, these undervalued pharma stocks offer opportunities in an overbought market.

Via InvestorPlace

Pharma ETFs Gain Post Q1 Earnings ↗

May 09, 2023

Pharma ETFs have been in the green over the past month.

Via Talk Markets

A Look At Pharma ETFs Post Q4 Earnings ↗

February 08, 2023

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month.

Via Talk Markets

5 Sector ETFs That Beat The Market In December ↗

December 27, 2022

While most segments of the market are suffering from huge losses, a few have performed really well. These are likely to continue outperforming should the trends prevail.

Via Talk Markets

Pharma ETFs In Focus Post Q3 Earnings ↗

November 09, 2022

Many industry bigwigs reported solid results with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month.

Via Talk Markets

Wave of Solid Q3 Earnings Push Pharma ETFs Higher ↗

November 09, 2021

The slew of Q3 results has led to smooth trading in pharma ETFs over the past month.

Via Talk Markets

Pharma ETFs in Focus Post Q1 Earnings ↗

May 12, 2021

The slew of Q1 results has led to mixed trading in pharma ETFs over the past month. Here are those in detail.

Via Talk Markets

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.